Moreover, in the future, as AD biomarkers are implemented in routine practice—whether as stand-alone tests (e.g., p-tau217) or as part of multi-test panels (e.g., NfL, GFAP)—accounting for demographic factors will likely require the development of cutoff matrices based on sex and age. This evidence concerns the gene NEFL and Alzheimer disease.